[ad_1]
After the exposure, the vaccine appeared to prevent damage to the lungs and prevent the virus from making copies there, but the virus continued to actively reproduce in the nose, according to Reuters.
Stephen Evans, professor of pharmacological epidemiology at the London School of Hygiene and Tropical Medicine, said the monkeys’ data was “good news” for sure, adding that “it is one of the obstacles that the Oxford vaccine is going through and he has removed it well. “
But while monkey success is seen as an important step, many vaccines that protect monkeys in the laboratory ultimately fail to protect humans.
According to Evans, one of the main results was particularly reassuring, since there was no evidence of a disease that improved the immune system. Instead of protecting against the virus, the vaccine made the disease worse.
He added: “This was a clear theoretical concern of the new coronavirus vaccine, and finding no evidence of this in this study is very encouraging.”
British researchers last month began administering doses of human volunteers in a small safety experiment, and researchers said that as of May 13, approximately 1,000 people had received the vaccine.
Globally, more than 100 experimental vaccines are being developed to combat the new Corona virus, which has so far infected more than 4.5 million people and killed more than 300,000.
The CEO of the company “AstraZeneca”, Pascal Suryot, had said that Great Britain would have a “priority” to supply the possible vaccine for the “Covid-19” epidemic, and stressed that the vaccine would be distributed at cost at the time of the epidemic.
The head of the pharmaceutical industry said that by June or July, scientists will know if the Coronavirus vaccine, which is being developed at the University of Oxford, will work.
“>
American and British researchers said Thursday that the new vaccine against the new Corona virus, which is being developed by scientists at Oxford University and closely monitored, appears protective, according to a small study of 6 monkeys.
The researchers noted that the vaccine achieved promising results that led to the start of human experiments late last month, according to preliminary results, which were not subject to strict review by other scientists, and was published Thursday in the “Bio Rexif” prepress site.
British pharmaceutical company “AstraZeneca” announced last month that it had collaborated with researchers from the Oxford Vaccine Group and the Jenner Institute to develop the vaccine, which was developed from a harmless virus that was genetically modified to carry part of the Corona virus, which causes Covid-19 disease.
According to the report, some monkeys that received a single dose of the vaccine developed antibodies to the virus within 14 days, and all protective antibodies developed within 28 days, before being exposed to high doses of the virus.
After the exposure, the vaccine appeared to prevent damage to the lungs and prevent the virus from making copies there, but the virus continued to actively reproduce in the nose, according to Reuters.
Stephen Evans, professor of pharmacological epidemiology at the London School of Hygiene and Tropical Medicine, said the monkeys’ data was “good news” for sure, adding that “it is one of the obstacles that the Oxford vaccine is going through and he has removed it well. “
But while monkey success is seen as an important step, many vaccines that protect monkeys in the laboratory ultimately fail to protect humans.
According to Evans, one of the main results was particularly reassuring, since there was no evidence of a disease that improved the immune system. Instead of protecting against the virus, the vaccine made the disease worse.
He added: “This was a clear theoretical concern of the new coronavirus vaccine, and finding no evidence of this in this study is very encouraging.”
British researchers last month began administering doses of human volunteers in a small safety experiment, and researchers said that as of May 13, approximately 1,000 people had received the vaccine.
Globally, more than 100 experimental vaccines are being developed to combat the new Corona virus, which has so far infected more than 4.5 million people and killed more than 300,000.
The CEO of the company “AstraZeneca”, Pascal Suryot, had said that Great Britain would have a “priority” to supply the possible vaccine for the “Covid-19” epidemic, and stressed that the vaccine would be distributed at cost at the time of the epidemic.
The head of the pharmaceutical industry said that by June or July, scientists will know if the Coronavirus vaccine, which is being developed at the University of Oxford, will work.
[ad_2]
